Is it time for genetic modifiers to predict prognosis in Duchenne muscular dystrophy?
- 12 June 2023
- journal article
- review article
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 19 (7) , 410-423
Abstract
Patients with Duchenne muscular dystrophy (DMD) show clinically relevant phenotypic variability, despite sharing the same primary biochemical defect (dystrophin deficiency). Factors contributing to this clinical variability include allelic heterogeneity (specific DMD mutations), genetic modifiers (trans-acting genetic polymorphisms) and variations in clinical care. Recently, a series of genetic modifiers have been identified, mostly involving genes and/or proteins that regulate inflammation and fibrosis — processes increasingly recognized as being causally linked with physical disability. This article reviews genetic modifier studies in DMD to date and discusses the effect of genetic modifiers on predicting disease trajectories (prognosis), clinical trial design and interpretation (inclusion of genotype-stratified subgroup analyses) and therapeutic approaches. The genetic modifiers identified to date underscore the importance of progressive fibrosis, downstream of dystrophin deficiency, in driving the disease process. As such, genetic modifiers have shown the importance of therapies aimed at slowing this fibrotic process and might point to key drug targets.Keywords
This publication has 130 references indexed in Scilit:
- ACTN3 genotype influences muscle performance through the regulation of calcineurin signalingJournal of Clinical Investigation, 2013
- THE 6‐minute walk test and other endpoints in Duchenne muscular dystrophy: Longitudinal natural history observations over 48 weeks from a multicenter studyMuscle & Nerve, 2013
- Osteopontin deficiency delays inflammatory infiltration and the onset of muscle regeneration in a model of muscle injuryDisease Models & Mechanisms, 2012
- Transforming growth factor (TGF)-β signaling in cardiac remodelingJournal of Molecular and Cellular Cardiology, 2011
- SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophyNeurology, 2011
- Latent TGF-β–binding protein 4 modifies muscular dystrophy in miceJournal of Clinical Investigation, 2009
- DMD Trp3X nonsense mutation associated with a founder effect in North American families with mild Becker muscular dystrophyNeuromuscular Disorders, 2009
- Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-βJournal of Clinical Investigation, 2009
- Late gadolinium enhancement: precursor to cardiomyopathy in Duchenne muscular dystrophy?The International Journal of Cardiovascular Imaging, 2008
- A polymorphism within a conserved β1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failureProceedings of the National Academy of Sciences, 2006